Updated Requirements for Pharmacovigilance in Clinical Trials

Summary

EMA has updated pharmacovigilance requirements for clinical trials in the EU, including enhanced SUSAR reporting timelines, mandatory electronic reporting through EudraVigilance, and new signal detection requirements during ongoing trials. Updated aggregate safety reporting formats are also specified.